The effect of curcumin on blood circulation for healthy vasodilatio

Not Applicable

Completed

• Conditions: Assessment of cardiovascular risk; Circulatory System

• Registration Number: ISRCTN90184217
• Lead Sponsor: OmniActive Health Technologies Inc.

Brief Summary

2016 Results article in http://www.ncbi.nlm.nih.gov/pubmed/27630772 Blood flow results 2019 Results article in https://pubmed.ncbi.nlm.nih.gov/31340534/ Effects on performance decrements following muscle-damaging exercise (added 10/01/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2015-05-30
• Study Start: 2015-12-22
• Last Update Posted: 23 January 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. Aged between 19 and 29 years inclusive
2. Meet the minimum recommendations for health and fitness by the American College of Sports Medicine
3. Non-smoking
4. Free from any musculoskeletal, medical or metabolic contraindications to exercise
5. Have not consumed any nutritional supplements and/or ergogenic aids for the preceding 9-week period and/or not have taken any anti-inflammatory medications for the previous month
6. Good general health as determined by a health history questionnaire
7. Female participamt must be currently taking oral contraceptive or post-menopausal (i.e. not pregnant)
8. Able to provide written and dated informed consent
9. Willing and able to comply with the protocol

Exclusion Criteria

1. Oarticipation in another clinical trial or consumption of investigational product within the previous thirty days
2. History of alcohol and/or drug abuse in the past 6 months or intends to consume either over the course of the study
3. Reported history of chronic or presence of treated or untreated bleeding disorder, diabetes mellitus, high blood pressure (systolic BP> 140 and/or diastolic BP> 90), thyroid disease, tachyarrhythmia, heart disease, kidney disease, or liver disease
4. Currently suffers from sleep disorder and/or has a known history of (or is currently being treated for) clinical depression, eating disorder(s) or any other psychiatric condition(s), which in the opinion of the investigator, might put the subject at risk and/or confound the results of the study
5. Subject has a known allergy or sensitivity to any ingredient in the test product
6. Any medical condition or uses any medication, nutritional product, dietary supplement or program, which in the opinion of the investigator, might interfere with the conduct of the study or place the subject at risk
7. History of difficulty swallowing large pills or tablets
8. Creatine use within 9 weeks prior to screening
9. History of orthopedic injury or surgery within the last 6 months
10. Has a contraindication to exercise utilized in research design
11. Subject has self-reported an abnormal resting ECG
12. Investigator is uncertain about subject’s capability or willingness to comply with the protocol requirements

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Flow mediated dilation is measured using ultrasound scanning at baseline and 8 weeks in all participants<br>2. Flow mediated dilation is measured using ultrasound scanning at baseline and 8 weeks in a subset of participants who had an FMD of 7% or lower